Drug company Zydus Cadila announced on Thursday that Brexpiprazole tablets, used for the treatment of Schizophrenia, have received market approval from the US health regulator in the American market.
Tentual marketing approval for Brexpiprazol tablets of 0.25, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg was granted to the Company by the United States Food and Drug Administration (USFDA), the medicine company said in a statement.
Brexpiprazole is an atypical antipsychotic for the treatment of major depressive disorders (MDD) and schizophrenia, and is indicated as an adjunctive therapy with antidepressants.
Zydus Cadila noted that it would manufacture the drug at its manufacturing facility at the SEZ, Ahmedabad.
The Ahmedabad-based group now has 321 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…